TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

COREPHARMA

CardiovascularRespiratoryImmunology
Pharma

COREPHARMA is a pharmaceutical company focused on Cardiovascular, Respiratory, Immunology.

1964
Since
20
Drugs
-
Trials
127
Approved (2yr)

Key Drugs

CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE
chlordiazepoxide hydrochloride
4 indications · 2020
NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE
diphenhydramine hydrochloride
· 2018

Recent Activity

AMLODIPINE BESYLATE 2026-02-17
Manufacturing (CMC)
AMLODIPINE BESYLATE 2026-01-26
Manufacturing (CMC)
AMLODIPINE BESYLATE 2026-01-22
BENAZEPRIL HYDROCHLORIDE 2026-01-13
Manufacturing (CMC)
DICYCLOMINE HYDROCHLORIDE 2025-09-15
Manufacturing (CMC)
CLORAZEPATE DIPOTASSIUM 2025-08-21
Labeling
CLORAZEPATE DIPOTASSIUM 2025-08-21
Labeling
CLORAZEPATE DIPOTASSIUM 2025-08-21
Labeling
CLORAZEPATE DIPOTASSIUM 2025-08-21
Labeling
CLORAZEPATE DIPOTASSIUM 2025-08-21
Labeling
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Cardiovascular 46%
4 drugs Phase 1: 1
Respiratory 20%
1 drugs Phase 2: 2 Phase 1: 1
Immunology 11%
1 drugs
Gastroenterology 11%
1 drugs
Dermatology 11%
1 drugs

Pipeline Strength Pro

Loading...

Competitors Pro

BAUSCH specialty
Dermatology, Immunology, Cardiovascular, Gastroenterology
Pfizer big-pharma
Dermatology, Immunology, Gastroenterology
Novartis big-pharma
Cardiovascular, Immunology, Respiratory
APOTHECON specialty
Dermatology, Cardiovascular, Gastroenterology, Respiratory
MALLINCKRODT specialty
Gastroenterology, Dermatology, Immunology, Respiratory